Tracing its history back to the medieval university founded in 1288 Universidade de Lisboa is currently undergoing a fusion with Universidade Técnica de Lisboa which will result in one of the leading universities in Europe. Universidade de Lisboa includes about 50 research units and 3 research institutes. The mission of the Instituto de Medicina Molecular (IMM) is to foster basic, clinical and translational biomedical research with the aim of contributing to a better understanding of disease mechanisms, developing novel predictive tests, diagnostics and therapeutic approaches. IMM is committed to excellence in Science. This goal is pursued by developing coherent research and development activities, an advanced training programme, and the recruitment of outstanding international young group leaders to establish leading research teams in Biomedicine.
Professor Alexandre de Mendonça is principal investigator at IMM. His main scientific areas of research are the cognitive decline of ageing and the neurophysiological basis for memory. Professor Mendonça participated and coordinated research projects on basic neurosciences as well as clinical trials in dementia and mild cognitive impairment. Professor Mendonça is member of the Scientific Committee of Portuguese Alzheimer Association, National Ethics Committee for Clinical Research and is the delegate from Portugal to the Dementia Panel of the European Federation of Neurological Societies. In addition to his background in basic neuroscience. Professor Mendonça has a research record in the early diagnosis of neurodegenerative disorders using neuropsychological tests and biomarkers. In his work he has also been concerned with the quality of life of people with prodromal and mild dementia and with carer support. Dr. Graça Melo is a nurse and nursing professor with large experience in assistance to patients with dementia as well as caregiver research. Dr. Tiago Mendes is a neuropsychologist with particular interest in cognitive rehabilitation. Dr. Helena Bárrios is devoted to quality of life research in patients with mild cognitive impairment and dementia.
Role in the consortium
IMM (UL) is partner in WP2, WP3 and WP4